Our Pipeline
ATXA Therapeutics has developed a novel series of highly selective antagonists of the TP receptor.
Amongst ATXA’s TP antagonist series is the lead candidate drug NTP42, as well as several other pipeline candidates, each with distinct pharmaceutical properties.
NTP42 and other candidates in this series have been extensively evaluated and have been confirmed to display excellent efficacy, specificity, and safety profiles in preclinical models and in the clinic following oral delivery.
Our Science
The TP
The thromboxane (TX) A2 receptor, known simply as the TP, controls signalling of the prostanoid TXA2 and the isoprostane 8-iso-prostaglandin F2α (8-iso-PGF2α), where this pathway regulates multiple processes, including inducing platelet aggregation and the constriction and proliferation of vascular and pulmonary smooth muscle.
TXA2/TP Signalling
TP-mediated signalling exerts potent pro-inflammatory, pro-mitogenic, and pro-fibrotic effects, and levels of both TXA2 and TP expression are elevated in many cardiopulmonary diseases, inflammatory disorders and in cancer progression and metastasis. TXA2/TP signalling also contributes to cardiac hypertrophy and fibrosis in multiple animal models.
TP Antagonists
TP antagonists are predicted to be potent inhibitors of vasoconstriction, platelet aggregation, inflammation and fibrosis, offering benefits to patients with cardiopulmonary diseases, reducing the potential for pulmonary vasoconstriction, remodelling, inflammation and fibrosis, while also directly benefiting the failing heart.
NTP42
In preclinical models of PAH, ATXA has confirmed the benefit of its lead NTP42 in the Sugen-Hypoxia (SuHx) and Monocrotaline (MCT) models, where it has shown benefit as a monotherapy and as a dual-therapy with other standard-of-care drugs. We continue to further this evidence in other cardiopulmonary and related disease indications.
Development Pipeline
Through our R&D, ATXA has built a pipeline of novel, highly selective small molecule drugs and has validated their efficacy potential in preclinical models of cardiopulmonary, acute pulmonary inflammation, oncology, and other diseases.
Our Pipeline is protected by a growing global patent estate and we have secured Orphan Designation from the EMA (Europe) and the FDA (USA) for our lead drug NTP42 for our initial target indication Pulmonary Arterial Hypertension (PAH).
* Phase I clinical trial (NCT04919863) was completed in healthy volunteers and confirmed safety & tolerability, drug exposure, and TP target engagement, pending formal reporting (late Q2, 2022). Diagram represents ongoing stages of development; does not correspond to the initiation or completion of a particular stage. NTP42:KVA4 is the formulated drug product name for NTP42.
**Alongside NTP42, TP20 & NTP48, ATXA are advancing additional TP antagonists in its drug pipeline across cardiopulmonary and other disease areas.
